Altre lingue Structure Therapeutics Inc.

Azioni

GPCR

US86366E1064

Biotecnologia

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 12/12/2025			Variaz. 5gg	Var. 1 gen.
67,06 ^USD	-0,56%		+94,04%	+147,27%

12/12	Le aziende sviluppatrici di farmaci per la perdita di peso si preparano a conquistare un mercato redditizio mentre la concorrenza si intensifica	RE
10/12	Structure Therapeutics Lancia un'Offerta Pubblica Incrementata da 650 Milioni di Dollari	MT

Altre lingue

Weight-loss drug developers line up to tap lucrative market as competition heats up	12/12
Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional ADSs	11/12
Structure Therapeutics Prices $650 Million Upsized Public Offering	10/12
Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants	10/12
Health Care Down Amid Intensified Obesity-Drug Competition - Health Care Roundup	08/12
Structure Therapeutics Plans $500 Million Public Offering	08/12
MÄRKTE USA/Anleger halten sich vor Zinsentscheid mit Käufen zurück	08/12
Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants	08/12
Top Midday Gainers	08/12
Sector Update: Health Care Stocks Lower in Afternoon Trading	08/12
Top Midday Stories: Paramount Launches $30-per-Share Bid for Warner Bros. Discovery; IBM to Acquire Confluent in $11 Billion Deal	08/12
Structure Therapeutics Shares Surge on Positive Phase 2b Results for Obesity Drug Aleniglipron	08/12
Wall Street : La décision de la Fed compte plus que ce que les marchés admettent	08/12
Weight-loss drug developers line up to tap lucrative market as competition heats up	08/12
Píldora contra la obesidad de Structure muestra pérdida de peso de hasta 11% en estudio de fase intermedia	08/12
Why the Fed's Next Move Matters More Than Markets Admit	08/12
Structure Therapeutics reports positive topline data from ACCESS program for its once-daily oral small molecule GLP-1 receptor agonist, aleniglipron	08/12
Structure's obesity pill shows up to 11.3% weight loss in study, shares double	08/12
Structure's experimental pill shows 11% weight loss in study, shares up	08/12
Structure Therapeutics : Aleniglipron Topline ACCESS Phase 2b Results	08/12
Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron	08/12
Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron	08/12
Structure Therapeutics Inc. to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025	08/12
Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025	08/12
USA-Les valeurs à suivre à Wall Street (actualisé)	05/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Trascrizioni Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Structure Therapeutics Inc.

Azioni

GPCR

US86366E1064

Biotecnologia

Altre lingue

Filtri